SG11201810137UA - Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof - Google Patents
Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereofInfo
- Publication number
- SG11201810137UA SG11201810137UA SG11201810137UA SG11201810137UA SG11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA
- Authority
- SG
- Singapore
- Prior art keywords
- pro
- international
- pct
- diseases
- human neutrophil
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 3
- 239000000816 peptidomimetic Substances 0.000 title abstract 3
- 230000002849 elastaseinhibitory effect Effects 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102000052502 human ELANE Human genes 0.000 abstract 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000007775 late Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210 | 2016-05-31 | ||
| PCT/EP2017/025156 WO2017207117A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810137UA true SG11201810137UA (en) | 2018-12-28 |
Family
ID=56108445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810138XA SG11201810138XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
| SG11201810137UA SG11201810137UA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
| SG10202113280XA SG10202113280XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810138XA SG11201810138XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202113280XA SG10202113280XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11235024B2 (zh) |
| EP (2) | EP3463280B1 (zh) |
| JP (4) | JP7286319B6 (zh) |
| KR (2) | KR102480800B1 (zh) |
| CN (3) | CN109195580A (zh) |
| AU (2) | AU2017273507B2 (zh) |
| BR (2) | BR112018074551B1 (zh) |
| CA (2) | CA3024521C (zh) |
| CL (2) | CL2018003390A1 (zh) |
| DK (2) | DK3463280T3 (zh) |
| EA (2) | EA039603B1 (zh) |
| ES (2) | ES2928050T3 (zh) |
| HR (2) | HRP20221194T1 (zh) |
| HU (2) | HUE060393T2 (zh) |
| IL (2) | IL263114B2 (zh) |
| LT (2) | LT3463280T (zh) |
| MA (2) | MA45167A (zh) |
| MX (2) | MX2018014752A (zh) |
| PH (2) | PH12018502522A1 (zh) |
| PL (2) | PL3463281T3 (zh) |
| PT (2) | PT3463280T (zh) |
| RS (2) | RS63639B1 (zh) |
| SG (3) | SG11201810138XA (zh) |
| UA (2) | UA125899C2 (zh) |
| WO (2) | WO2017207117A1 (zh) |
| ZA (2) | ZA201807772B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024521C (en) * | 2016-05-31 | 2023-06-20 | Polyphor Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
| CA3151997A1 (en) * | 2019-08-23 | 2021-03-04 | Ph Pharma Co., Ltd. | Use of a neutrophil elastase inhibitor in lung disease |
| AU2021213776A1 (en) * | 2020-01-30 | 2022-08-25 | Vertex Pharmaceuticals Incorporated | Methods of treatment for alpha-1 antitrypsin deficiency |
| IL303021A (en) * | 2020-11-23 | 2023-07-01 | Spexis Ag | Peptidomimetic beta-herpain compositions and spray dosage forms thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU744918B2 (en) | 1996-11-01 | 2002-03-07 | Xoma Corporation | Therapeutic uses of BPI protein products in cystic fibrosis patients |
| CA2593112A1 (en) | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
| CA3035941C (en) * | 2005-02-17 | 2021-11-16 | Polyphor Ltd. | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| EP1981572B1 (en) * | 2006-02-09 | 2012-11-21 | Kamada Ltd. | Pulmonary delivery of alpha-i proteinase inhibitor |
| TR201807714T4 (tr) * | 2006-02-10 | 2018-06-21 | Pari Pharma Gmbh | İnhalasyon tedavisine yönelik nebülize antibiyotikler. |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| PT2567691E (pt) * | 2011-09-12 | 2015-04-09 | Pari Pharma Gmbh | Composições aquosas que compreendem arbecacina |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| WO2015098872A1 (ja) | 2013-12-26 | 2015-07-02 | 株式会社カネカ | 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール |
| RS63543B1 (sr) * | 2013-12-27 | 2022-09-30 | Spexis Ag | Peptidomimetici strukture beta-ukosnice kao selektivni inhibitori elastaze |
| AU2013409231B2 (en) * | 2013-12-27 | 2019-08-01 | Polyphor Ag | Beta-Hairpin peptidomimetics as selective elastase inhibitors |
| CA3024521C (en) * | 2016-05-31 | 2023-06-20 | Polyphor Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
-
2017
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en active Active
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt active IP Right Grant
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en active Active
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 JP JP2018562549A patent/JP2019523222A/ja active Pending
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active IP Right Grant
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en unknown
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 MX MX2018014752A patent/MX2018014752A/es unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active IP Right Grant
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 CA CA3024522A patent/CA3024522A1/en active Granted
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt active IP Right Grant
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201810137UA (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201900471VA (en) | Combination therapy for copd | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen |